Fractionation of an extract from American sycamore leaves produced the small molecule, kaempferol-3-O-alpha-L-(2",3"-di-p-coumaroyl)rhamnoside (KCR), which exists in four stereoisomeric forms (EE, EZ, ZE, and ZZ) at the olefin in the p-coumaroyl; all four isomers exhibit potent anti-MRSA activity in vitro. As part of the preclinical development of KCR, we set out to investigate the metabolites of KCR in mouse plasma as a prelude of ADME studies and therapeutic assessment. When KCR was added to mouse plasma at 37 ºC, two new HPLC peaks appeared with increasing intensity as the incubation time increased; their retention times were shorter than that of KCR indicating that KCR was metabolized to produce two compounds that were more polar. HPLC results indicated that the two metabolites mainly came from the ZE and EE isomers and that the ZZ isomer was the most stable. Based on their respective HPLC retention times and UV spectra, these two metabolites were tentatively identified as p-coumaric acid and afzelin; both of which are more polar than KCR. The molecular weights of both metabolites were then confirmed by a Waters Acquity UPLC system with a QDa mass detector. UPLC chromatograms and molecular ions of metabolites 1 and 2 match well with those of reference materials, p-coumaric acid and afzelin, thus confirming the identities of the two major metabolites of KCR. In summary, KCR was metabolized in mouse plasma and two major metabolites (p-coumaric acid and afzelin) were identified; the metabolites were mainly converted from the ZE and EE isomers.
Staphylococcus aureus (S. aureus), is a type of bacteria that can cause deep tissue infections but normally resides on surfaces and does not usually cause any harm to the host. Among the S. aureus bacteria, methicillin-resistant S. aureus (MRSA) causes the greatest patient mortality and extends hospital stays. MRSA alone is estimated to kill around 19,000 people every year in the U.S. [1, 2] . Recently, MRSA has emerged as a community-associated pathogen (CA-MRSA), infecting individuals who have not either been hospitalized or undergone a medical procedure [3] . Furthermore, MRSA is also known to be a common skin colonizer and causes the same spectrum of infections as methicillin-susceptible S. aureus (MSSA) infections [4] .
Currently, vancomycin is being used as the drug of choice for MRSA infections even though it is only successful in 35-57% of the infections [5] . Vancomycin has to be administered by i.v. injection/infusion which may require prolonged hospitalization. Further, the increased use of vancomycin has resulted in the emergence of vancomycin-resistant S. aureus (VRSA); the first VRSA strain was isolated from a patient in 2002 [6, 7] . Oral  antibiotic  choices  for  MRSA  include  trimethoprimsulfamethoxazole  (TMP-SMX) , clindamycin, doxycycline, minocycline, linezolid and rifampin. TMP-SMX is a sulfonamide antibiotic and was used as the initial antibiotic for CA-MRSA infection; however, it is associated with several potentially serious adverse reactions and not suitable for general use [8] . Clindamycin is another antibiotic frequently used as an initial therapeutic option but resistance to clindamycin can develop rapidly [9, 10] . Doxycycline and minocycline also have been reported to be effective therapy for MRSA/CA-MRSA [11, 12] . Linezolid has been used in central nervous system (CNS) MRSA infections and has similar efficacy as vancomycin; oral bioavailability results in decreased hospital stays and therapeutic costs [13] . Rifampin has been used in combination with other antibiotics, such as TMP-SMX, clindamycin, or doxycycline/minocycline since resistance may develop rapidly if it is used as monotherapy [14] .
The most effective anti-MRSA drug used currently is daptomycin, a cyclic lipopeptide derived from Streptomyces roseosporus. Daptomycin is useful in treatments of short duration and persistent MRSA un-affected by other drug treatments [15] . Its mechanism of action involves binding to the bacterial cell membrane, which causes depolarization of the membrane resulting in bacterial cell death [16] . Unfortunately, the FDA has reported serious side effects for daptomycin, including an increase in blood creatine phosphokinase, rhabdomyolysis, skin exfoliation, and skin ulcers. Thus, there is a significant and urgent need for novel antimicrobial agents that can effectively combat these new strains of drugresistant "superbugs" [17] ; natural products, including plants, are promising sources of anti-MRSA agents.
Platanaceae is a family of flowering plants with a long history of use in traditional folk medicines. One of the species of Platanus native to North America is Platanus occidentalis, also known as American sycamore [18, 19] . Native Americans used sycamore for cold and cough remedies as well as dermatological, respiratory, and gastrointestinal aids. Sycamore bark has been used as an analgesic for internal pain and sycamore leaves also have been used as a remedy in the control of diarrhea [20] .
American sycamore is a native US species already in culture for timber and pulp production as well as an ornamental and shade species. In a recent study, Ibrahim et al. isolated a group of glycosides from the leaf extract of American sycamore [5] . Fractionation of the ethanolic extract produced an active molecule kaempferol-3-O-alpha-L-(2",3"-di-p-coumaroyl)rhamnoside (KCR) in four stereoisomeric forms (EE, EZ, ZE, and ZZ) ( Figure 1 ). All four isomers exhibit potent anti-MRSA activity both in cultures and in animal models [5, 21] . This represents the first plant-derived antibiotic to prevent growth of MRSA both on surfaces and systemically.
For the development of any drugs, pharmacokinetics studies are essential. As part of the preclinical development of KCR, we set out to investigate the potential metabolites of KCR in mouse plasma as a prelude for ADME studies and therapeutic assessment. In addition, the major metabolites of these anti-MRSA extracts may possess a novel mechanism of action as they do not show structural homology with established antibiotics [22] . Figure 2 is presented to help facilitate the analysis and understanding of the potential metabolites of KCR. Basically, KCR consists three components: kaempferol, rhamnose, and p-coumaric acid; without p-coumaric acid, KCR becomes afzelin. It was suspected that one or more of these components of KCR could be the metabolite(s).
In mouse plasma, the assignment of each isomer peak of KCR was made by comparing with the respective chromatogram of each isomer. As shown in Fig. 3 , all 4 isomers of KCR were reduced over 24 hr; EE appeared to be the easiest to be metabolized and ZZ appeared to be the most stable. Meanwhile, two new peaks (at ca. 2.3 and 3.7 min) were observed at 1 hr and at 24 hr with increased intensity indicating that they were the major metabolites of KCR (metabolites 1 and 2) in mouse plasma. A minor new peak was observed at ca. 6 min. However, its intensity was much weaker than these two major isomers, especially at 24 hr, indicating that it might be an intermediate metabolite with less significant role. In addition, this weak peak was not observed at a concentration suitable for the analysis of metabolite 1 and 2 by the UPLC/mass analysis.
In order to confirm the identities and match the molecular weights of these two metabolites, UPLC/mass data on metabolized KCR were obtained to compare with the data from HPLC. Due to the switching from HPLC system to UPLC/Mass system and different chromatographic methods used, the observed retention times for the two metabolites were different (Figure 4a ). Figure 4b shows the UV spectra of both metabolites 1 and 2, which are the same as those observed in the HPLC run (not shown) respectively. -ion of kaempferol (mw 286), which was resulted from the cleavage of the ether bond to separate rhamnose from afzelin. These results indicate that metabolite 1 is p-coumaric acid and metabolite 2 is afzelin.
Injections of two authentic reference materials, p-coumaric acid and afzelin, in the UPLC/mass system further proved the identities of the two major metabolites of KCR in mouse plasma (UPLC chromatograms and mass spectra are provided in the Supplementary Data Section) . It was found that p-coumaric acid by itself showed the same retention time and the same molecular mass as those Based on the paper by Bahar et al., carboxyesterase is abundant in mice and should be considered in preclinical studies [23] . It is thus suspected that the fast metabolism of KCR in mouse plasma may be mainly due to carboxyesterase cleaving the ester bond between afzelin and p-coumarc acid. However, further studies are needed in order to fully understand the in vitro metabolism of KCR in mouse plasma. In summary, KCR was rapidly metabolized in mouse plasma in vitro to produce two major metabolites, p-coumaric acid and afzelin. These two metabolites mainly came from the ZE and EE isomers of KCR within 24 h; the EZ and ZZ isomers were much more stable. These two metabolites were first identified via an HPLC method by comparing their retentions and UV spectra. The molecular weights of both metabolites were then confirmed by a Waters UPLC/mass system. These data suggest that isomerization of the p-coumaroyl group represents a unique mechanism that may be exploited by the tree in nature and could be utilized to slow drug resistance in the development of this new class of antibiotics.
Experimental
Instruments: A Waters Alliance HPLC system (including a Waters 2690 Separations Module, a Waters 2996 Photodiode Array Detector, a Waters Nova-Pak® C18 reversed-phase column (3.9 x 300 mm, 4 µM particle size), and the Waters Empower software (Milford, Massachusetts) were used as the main instruments to determine the metabolites.
A Waters Acquity UPLC® System, an Acquity UPLC BEH C18 column (2.1 x 50 mm, 1.7 µM particle size), a PDA detector, a QDa mass detector in tandem, and the Waters Empower software (Milford, Massachusetts) were used in this study to confirm the molecular weights of the metabolites of KCR.
A Beckman Coulter Allegra 21R Centrifuge (Fullerton, California, USA) was used to prepare the plasma and plasma samples for HPLC and UPLC injections. An Eppendorf Vacufuge™ was used to evaporate the solvent during the sample prep.
Reagents: KCR (HPLC peak purity > 97 %) was extracted and purified by Dr. Mark Hamann as previously described [5] . Individual stereoisomers (KCR in EE, EZ, ZE, and ZZ forms with HPLC peak purity > 97%) were provided by Dr. Jim McChesney (Ironstone Separations, Inc., MS). Authentic Afzelin and pcoumaric acid were purchased from Sigma (reagent grade) without further purification. All solvents were HPLC grade and obtained from Burdick & Jackson (Muskegon, Michigan, USA).
Investigation of KCR metabolites in mouse plasma: KCR and its 4 individual isomers at 100 µg/mL in EtOH (25 µL) respectively were added to each 1.5 mL conical centrifuge tube containing 225 µL of mouse plasma (NIH Swiss, female, 6-8 wk), vortexed, and incubated at 37 ºC. At predetermined time points up to 24 hr, the reaction was quenched by adding 800 µL of ethyl acetate and vortexed. Each sample was then centrifuged at 14,000 rpm (equivalent to 19,280 g) for 15 min at room temperature and the upper organic phase was transferred to a new 1.5 mL conical Eppendorf® tubes and evaporated to dryness employing an Eppendorf Vacufuge® at 45 ºC. The residue was reconstituted by adding 225 µL of ethanol, vortexed, centrifuged, and the supernatant was injected into the Alliance HPLC System or the Acquity UPLC/QDa System. To prepare a plasma control, EtOH (25 µL) and ethyl acetate (800 µL) were added to each plasma sample and processed the same way as the spiked plasma samples. 
